EPO and anemia (phenotype): The prolyl hydroxylase inhibitors (PHIs), which act by stabilizing HIFα to stimulate endogenous EPO production (Figure 2), are promising new agents for treating anemia of chronic kidney disease and perhaps other etiologies165,166.